Status:
UNKNOWN
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurre...
Detailed Description
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurrence or recurr...
Eligibility Criteria
Inclusion
- H. pylori infected patients who have willingness to receive eradication therapy
Exclusion
- (1) history of gastrectomy, (2)gastric malignancy, including adenocarcinoma and lymphoma, (3) previous allergic reaction to antibiotics (amoxicillin, clarithromycin), N-acetyl cysteine and prompt pump inhibitors (dexlansoprazole), (4)contraindication to treatment drugs, (5) pregnant or lactating women, (6) severe concurrent disease. (7) phenylketonuria (8) Patients who cannot give informed consent by himself or herself.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2016
Estimated Enrollment :
654 Patients enrolled
Trial Details
Trial ID
NCT02249546
Start Date
September 1 2014
End Date
October 1 2016
Last Update
September 25 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan Univeristy Hospital
Taipei, Taiwan, Taiwan
2
Department of Internal Medicine, National Taiwan Univeristy Hospital Yun-Lin branch
Douliu, Yunlin County, Taiwan, 640